Novartis hands off experimental tuberculosis drugs to TB Alliance in move...
ZURICH (Reuters) – Novartis has signed a licensing deal to hand over its experimental tuberculosis (TB) drugs to the Global Alliance for TB Drug Development, joining a growing Big Pharma …
View ArticleViaCyte, Janssen ink deal over stem cell-derived islet replacement therapy...
US regenerative medicine company ViaCyte Inc said Thursday it had signed a rights deal with Janssen Research & Development LLC, part of US Johnson & Johnson (NYSE:JNJ), under which Janssen …
View ArticleRoche is beefing up its respiratory drug portfolio with InterMune takeover
Swiss Roche (VTX:ROG) has agreed to purchase California-based pulmonology and fibrotic disease therapy maker InterMune Inc (NASDAQ:ITMN) for USD 8.3 billion (EUR 6.3bn), or USD 74.00 apiece, …
View ArticleAvalon-GSK Collaboration Generates Two More Startups in San Diego
Bruce V. Bigelow San Diego’s Avalon Ventures is taking the wraps off two new startups today, with each one getting as much as $10 million in Series A financing through …
View ArticleMerrimack, Baxter Ink $970M+ Deal for Pancreatic Cancer Drug
Ben Fidler It’s been an up and down year for Merrimack Pharmaceuticals. On one hand, the Cambridge, MA-based company succeeded in a Phase 3 trial in the notoriously tough field …
View ArticleShould I Stay Or Should I Go? Big Pharma Execs Taking The Biotech Plunge
That’s the dilemma facing drug hunters as leadership roles in biotech become more and more attractive. You may have noticed that more and more seasoned pharma executives are making …
View ArticleHealthPrize inks deal to track medication adherence for injectables
HealthPrize Technologies has inked a deal with West Pharmaceuticals that will expand the company’s medication adherence meets gaming technology to injectable drugs that are self-administered, according...
View ArticleTexas Medical Center Makes Pitch to Boost Houston Biotech Startups
Angela Shah The Texas Medical Center is slated this week to unveil its new life sciences accelerator, to be housed in a former Nabisco cookie factory near its main Houston …
View ArticleLowering the Cost of Failure in Biopharmaceuticals
Court Chilton In any business, projects fail, but in biopharmaceuticals, the consequences of failure are especially damaging. Projects in the industry tend to be long and expensive—from clinical...
View ArticleCystic Fibrosis Drug Developer N30 Pharmaceuticals Raises $30M
Michael Davidson N30 Pharmaceuticals, a Boulder-based pharmaceutical company developing drugs for cystic fibrosis, announced yesterday it has raised a $30 million mezzanine financing round. N30 Pharma...
View ArticleArray and Novartis End Development Deal for Cancer Drug Binimetinib
Michael Davidson Drug developer Array BioPharma and pharmaceutical giant Novartis are going separate ways, but that doesn’t seem to be bad news for Boulder, CO-based Array. The companies announced...
View ArticleOncothyreon Pays $20M for Array BioPharma’s Breast Cancer Drug
Michael Davidson Oncothyreon and Array BioPharma announced today that they have updated their development agreement around a breast cancer drug invented by Array. Oncothyreon, based in Seattle, will...
View ArticleInsulin inhaler Afrezza could launch in U.S. next year under Sanofi-MannKind...
French pharmaceutical group Sanofi (EPA:SAN) and US biopharmaceutical company MannKind Corp (NASDAQ:MNKD) have signed a global exclusive licence deal to develop and market Afrezza (insulin human)...
View ArticleJapan’s Chugai Pharmaceuticals: We’re not being acquired by Roche
Japan-based Chugai Pharmaceuticals has released a statement that denies reports that the company is to be acquired by Roche, a Swiss drug company, it was reported yesterday. The Japanese company ...
View Article10 Bits of Advice for Students Interested in Drug Development
Daniel Sem Here are my 10 crucial pieces of advice for students who aspire to a career in pharmaceutical labs: 1. You need a solid foundation in science. Master the (Read more...)
View Article